68 results about "Immunological Adjuvants" patented technology

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

Abstract Compositions comprising an emulsion and aluminum salt nano-/micro-particles surface stabilized with at least one surfactant are useful as immunological adjuvants. The emulsion of these compositions comprises at least one oil; at least one surfactant; a plurality of surfactant vesicles; optionally at least one sterol; and an aqueous phase. The present invention also provides vaccines comprising one or more antigens combined with the emulsion and surface stabilized aluminum salt particles of the present invention, or one or more antigens combined with non-ionic surfactant vesicles.

The present invention provides methods for preparing TLR-4 receptor agonist E6020:

and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates.

An immunoadjuvant used to prepare the antiviral vaccine or medicine for increasing the immune activity of the antigens for HBV, HCV, SARS coronavirus, fowl influenza virus, etc is a kind of human or animal's novel heat shock proteins gp96, hsp108 and hsp70.

The invention relates to an immunological adjuvant containing fucosan sulfate and application of the immunological adjuvant. The technical problems that at present, the kinds of immunological adjuvants are few, side effects cannot be avoided, and a great number of vaccines need to be provided when infectious diseases break out are solved. The immunological adjuvant consists of the following components in mass ratio: fucosan sulfate, ginsenoside and the rest of carriers, wherein the carriers consist of the following components in mass ratio: an emulsifying agent, an emulsifying auxiliary agent, oil phase and aqueous phase. The immunological adjuvant can be widely used in the preparation field of vaccines.

The invention relates to a traditional Chinese medicine immunopotentiator (an astragalus polysaccharide immunopotentiator for short) prepared from astragalus extracts and sulfated epimedium polysaccharides, which belongs to the field of immunological adjuvants of livestock and poultry. 1,000ml of the liquid medicine is prepared from 40g of astragalus and 120g of epimedium herb. The preparation method of the immunopotentiator comprises the following steps of: decocting the astragalus with water for three times, then merging the obtained filter liquor and condensing the filter liquor into 500ml of astragalus solution; extracting the epimedium polysaccharides by using the epimedium herb water decoction and ethanol precipitate method, then decorating the polysaccharides by using the chlorosulfonic acid-pyridine method, and preparing the polysaccharides into 500ml of sulfated epimedium polysaccharide solution after carrying out distilled water dialysis on the polysaccharides; and mixing the astragalus solution and the sulfated epimedium polysaccharide solution, and then filtering, sub-packaging and sterilizing to obtain the traditional Chinese medicine astragalus polysaccharide immunopotentiator. The immune experiment shows that the astragalus polysaccharide immunopotentiator has the advantage of obviously improving the proliferation of peripheral blood lymphocyte of chicken and enhancing the cellular immunity, obviously improving the potency of a serum antibody, promoting the lymphocyte proliferation, enhancing the cellular immunity and humoral immunity, and improving the immune response of a vaccine by coordinately immunizing chickling by using the Newcastle disease vaccine.

The invention discloses a compound-type nano-vaccine taking an amphiphilic three-block polymer of polyethylene glycol derivative-poly lysine-poly leucine as a nano-carrier bearing a tumor antigen, an immunological adjuvant and siRNA (si Ribonucleic Acid), and a preparation method of the compound-type nano-vaccine. According to the nano-vaccine, taking and presenting of the antigen by antigen-presenting cells can be improved by a nano-micelle bearing the antigen; siRNA is efficiently delivered to TADCs (Tumor-associated Dendritic Cells) to block immunosuppression signals of TADCs, and TADCs are induced and activated by collaboration with the immunological adjuvant, so that a tumor resisting effect of a tumor vaccine is improved; the nano-vaccine has the advantages that the adopted carrier of the nano-vaccine is good in biocompatibility and low in toxicity, and is degradable in a biological body; degradation products are nontoxic and harmless, and can be absorbed or metabolized; and the preparation method of the nano-vaccine is simple and convenient and feasible, good in stability and convenient for popularization.

The invention provides the immunomodulator with the free adjuvant having the function of preventing and curing the insulin-dependent diabetes mellitus. Aiming at the weak immunogenicity, the antigen epitope polypeptide gene (a length of antigen epitope p277 rooted from human HSP60) is associated repeatedly six times and inserted repeatedly into the backward position of the heat shock protein HSP65 gene rooted from the mycobacterium bovis, the fusing expression between the repeat series connecting antigen polyeptide and the HSP65 is realized. The produced fusing albumen did not need the adjuvant; the antigen polyeptide don't need be coupled with the carrier chemistry to the immunity. The fusing albumen can inspire the organism to produce the high titer aiming at p277 by means of the mucous membrane immunity, so the nosogeny of NOD chmice diabetic are depressed highly. The invention can prevent the 1 type and 1.5 type diabete characterized in depending on the insulin.

Immunogenic compositions and kits, as well as methods of stimulating immune responses and methods of immunization using the same. The compositions and kits comprise: (a) an antigen derived from Bacillus anthracis; (b) polymer microparticles comprising a biodegradable polymer; and (c) a polynucleotide-containing immunological adjuvant.

The invention discloses a Bacillus amyloliquefaciens WH3 strain, and a preparation method and application thereof. The preparation method comprises the following steps: 1, separation and identification of bacteria: separating bacteria resistant to rape sclerotinia rot from rape seedlings, and carrying out 16SrDNA and morphological identification to determine that the WH3 strain obtained by separation is Bacillus amyloliquefaciens; 2, separation, purification and identification of an antifungal active substance Safenour: fermenting the WH3 strain, extracting the antifungal active substance, separating and purifying through a sephadex column, and carrying out MALDI-TOF (matrix-assisted laser desorption/ionization-time of flight ) mass spectrometry on the active antifungal substance to inferthat the substance is a ring type polypeptide; and 3, application of the strain in the preparation of vaccines and immunological adjuvants. After the Safenour used as the adjuvant is mixed with a protein antigen and mice are respectively immunized through oral administration and injection of the mixture, effective body fluid and cellular immune response can be activated, and a high-titer specificantibody can be detected in the blood serum. The Safenour has low production cost and high stability, does not need to be emulsified when mixed with the antigen, and has a better immunoenhancement effect in comparison with Freund adjuvants and cholera toxin B subunits.

A method for preparing purified yeast is disclosed, where the squalene source is a yeast that hyper-produces squalene. The squalene is useful for pharmaceutical purposes. For instance, it can be used to prepare an oil-in-water emulsion, and the emulsion is particularly suitable for use as an immunological adjuvant.

The invention relates to a compound immunological adjuvant comprising a water phase solution and an oil phase solution which are respectively prepared, wherein the water phase solution is a CpG water solution the concentration of which is 0.5 to 2.0mg/mL; the oil phase solution is an imiquimod white oil solution the concentration of which is 0.25 to 1.0mg/mL; and the volume ratio of the water phase solution to the oil phase solution is 1:6. The invention also relates to a vaccine prepared from one or more antigens selected from attenuated live full microorganisms, inactivated microorganisms, recombinant peptide and proteins, synthetic peptide and cracked microorganisms and the water phase solution and the oil phase solution in the compound immunological adjuvant according to the volume ratio of 1:1:6. By the compounding of imiquimod, CpG and a white oil component, the compound immunological adjuvant has an obvious synergistic effect and enhances the immunological activity reactions of Th1 and Th2, so that the activity of stimulated immunological cells is obviously enhanced.

The compound ginseng-astragalus immunopotentiator for enhancing immunological function of animal is injection, each 1000 ml of which contains ginsenoside 0.75 g and astragalus polysaccharide 3.0 g except water for injection. The compound ginseng-astragalus immunopotentiator may be used alone to enhance the cellular immunity and humoral immunity or as immunological adjuvant to result in excellent immunopotentiating effect. Pharmacological test shows that the immunopotentiator can raise the expression of chicken's peripheral blood T lymphocyte IL-2mRNA and IFN-gamma-mRNA. Safety test shows that the immunopotentiator has no irritation and no toxicity.

A pharmaceutical composition to be administered to mammals via the mucosal route consisting of a vehicle system comprising mono-/dietherglycerides conjugated with a water soluble polymer groups selected from PEG's containing 2-30 polyoxyethylene units, an antigen and optionally a bacterial toxin for the augmentation of immune responses for vaccination, immunisation, treatment of allergy, treatment of cancer, treatment of infectious disease, treatment of an autoimmune disease, Alzheimer's, substance addiction or the treatment of a disease which is fully or partially controlled by the body immune system.

The invention relates to a method for extracting effective components of Mycobacterium, aims at removing lipid components, reducing side effects, remaining effective components thereof and leading to a function of immunological adjuvant, and comprises the strain of Mycobacterium and application of the extract thereof on the prevention and treatment of tuberculosis.

The invention relates to compound intranasai immunization adjuvant used for deactivated avian influenza antigen, belongs to biotechnical field, and is special for the application of deactivated avian influenza antigen. The compound adjuvant is mixed or combined by CpG DNA and sodium cholate according to weight ratio of 5:2 according to dosage of immunological adjuvant of 0.1mg/kg. through combining with deactivated avian influenza antigen and intranasai immunization, the inventive compound intranasai immunization adjuvant used for deactivated avian influenza antigen can effectively local immunity of mucous membrane and humoral immunity of whole body, avoid immunization schedule through intramuscular injection, reduce stress reaction of chickens, provide guarantee for improving chicken quality, and provide an ideal Immunization approach for prevention of avian influenza.

The present invention belongs to the technical field of medicine, and particularly to the field of vaccines and immunizations, more particularly to a radix achyranthis bidentatae crude polysaccharide, a radix achyranthis bidentatae polysaccharide component and a radix achyranthis bidentatae homogeneous polysaccharide extracted from radix achyranthis bidentatae, wherein the radix achyranthis bidentatae crude polysaccharide is selected from a radix achyranthis bidentatae crude polysaccharide 1 and a radix achyranthis bidentatae crude polysaccharide 2, wherein the radix achyranthis bidentatae crude polysaccharide 1 mainly comprises fructose, has a molecular weight of 1000-3000 Da, and preferably contains a small amount of glucose, and the radix achyranthis bidentatae crude polysaccharide 2 mainly comprises arabinose, glucose, Rhamnose, galactose and galacturonic acid, and has a molecular weight of 1.0*10<4>-2.0*10<5>Da. The present invention further relates to a pharmaceutical composition containing the polysaccharide, preparation methods of the polysaccharides, and vaccine uses of the polysaccharides. According to the present invention, the radix achyranthis bidentatae crude polysaccharide, the radix achyranthis bidentatae polysaccharide component and the radix achyranthis bidentatae homogeneous polysaccharide respectively have good immunoadjuvant activity and good immunomodulatory effects, and have the potential in preparation of vaccine adjuvants and immunomodulatory drugs.

The present invention belongs to the field of biomedical engineering, in the more concrete, said invention relates to a new type ultrasonic microvesicle which can be used as immunological adjuvant and vaccine carrier. It is characterized by that the vaccine antigen substance is adhered on the microvesicle surface and/or covered in microvesicle interior so as to synthesize the vaccine antige carried ultrasonic microvesicle. When it is used, the vaccine antigen carried ultrasonic microvesicle can systematically or locally act on target tissue, the ultrasonic wave can be used to break the microvesicle of target tissue area, and orietationally release vaccine antigen substance so as to raise the immunological activity of antigen.

A polymer protein (VP2/VP4/VP3) gene of infectious Fabricius bursa virus (IBDV) for intensifying the immunogenicity of vaccine and a recombinant carrier using pCI as eukaryon expression vector and containing said coding sequence are disclosed. The expression ability of said recombinant carrier increase by 10-40 times than normal eukaryon carrier. A DNA vaccine for infectious Fabricius bursa virus is also disclosed, which contains said eukaryon expression plasmid and immunological adjuvant and features high safety, stability and effect.

The present invention relates to immunological adjuvant, and is especially a kind of poplar bark lipoid used as immunological adjuvant and its preparation process and usage. The adjuvant is prepared with coarse extracted lipoid liquid and through stirring, filtering and cooling under certain condition in bacteria-free environment. The adjuvant is easy to maintain and transport without needing special apparatus. The mixture of the adjuvant and antigen in certain ratio is used to immunize animal to produce immunity fast and with less allergy. Immunizing hen with the mixture can also raise laying rate.

The invention provides a taxus mairei immunological adjuvant and an influenza vaccine containing the same. The taxus mairei immunological adjuvant is characterized by consisting of the following components in percentage by mass: 0.001 to 100 percent of taxus madia extract, and 0 to 99.999 percent of vector. The immunological adjuvant can better improve the immunogenicity of the vaccine, and greatly reduces the consumption of vaccine antigens; the consumption of the vaccine antigens used by using the taxus mairei extract as the adjuvant is half of the consumption of vaccine antigens used by only using aluminum hydroxide as the adjuvant or less, and ideal immunological protective effect can be achieved likewise; the immunological adjuvant has high safety and low side effect; and a method for preparing the influenza vaccine by using the taxus mairei extract as the adjuvant is simple and convenient, and the quality of the vaccine is easy to control.

The invention relates to an immunomicrosphere for overcoming B cell immunological tolerance and application thereof. The immunomicrosphere comprises a microsphere medium, wherein the outside of the microsphere medium is coated with vaccine antigen, and the inside of the microsphere medium is coated with immune carrier protein for activating T cells. The invention also relates to application of the immunomicrosphere for overcoming the B cell immunological tolerance in preparing vaccines and immunological adjuvants. By using the technical scheme, the immunomicrosphere is combined with B cell receptor through the antigen and phagocytized by B cells, and the carrier protein is released and degraded in the cells; the immunomicrosphere is presented to Th cells through B cell MHC II to activate the TH cells to release cell factors, thereby promoting the activation and proliferation of the B cells; and high-titer antibody is generated through the affinity maturation process. The antigen protein and the immune carrier protein are respectively arranged on the surface of the microsphere and inside the microsphere, thereby preventing the antigen protein epitope and the Th cell activation epitope from competing with the B cell receptor.